NextCure, Inc. (NXTC): Price and Financial Metrics
GET POWR RATINGS... FREE!
NXTC Stock Price Chart Interactive Chart >
NXTC Price/Volume Stats
| Current price | $4.65 | 52-week high | $9.18 |
| Prev. close | $4.77 | 52-week low | $3.25 |
| Day low | $4.65 | Volume | 300,700 |
| Day high | $4.88 | Avg. volume | 153,264 |
| 50-day MA | $4.20 | Dividend yield | N/A |
| 200-day MA | $5.67 | Market Cap | 129.02M |
NextCure, Inc. (NXTC) Company Bio
NextCure, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.
Latest NXTC News From Around the Web
Below are the latest news stories about NextCure Inc that investors may wish to consider to help them evaluate NXTC as an investment opportunity.
Needham Maintains Their Buy Rating on NextCure (NXTC)In a report released today, Gil Blum from Needham maintained a Buy rating on NextCure (NXTC – Research Report), with a price target of $14.00. The company's shares closed last Monday at $5.94, close to its 52-week low of $5.59. According to TipRanks.com, Blum has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -28.1% and a 7.0% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Rocket Pharmaceuticals. NextCure has an analyst consensus of Strong Buy, with a price target consensus of $20.67. |
NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual MeetingBELTSVILLE, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data in oral and poster presentations at the American Society of Hematology (ASH) annual meeting in Atlanta, Georgia, and on a virtual platform. The data come from preclinical research studies in collaboration with Emory Unive |
NextCure to Present at The JMP Securities Hematology and Oncology SummitBELTSVILLE, Md., Nov. 30, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday December 7th at 11:40 am ET. A live audio webcast will be available through the Investors section of the company’s website |
NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare ConferenceBELTSVILLE, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in the Piper Sandler Virtual 32nd Annual Healthcare Conference on November 30th. An audio webcast of the pre-recorded The post NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference appeared first on ForexTV . |
NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual MeetingBELTSVILLE, Md., Nov. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data from two clinical studies and one research study presented at the Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C., and on a virtual platform. The data come from clinical studies evaluating NC318, a Siglec-15 (S15) antibody, and NC410, a fusion protein of LAIR-2, in patients with advanced/metastatic solid tumors, as well as from a research study evaluating NC410s impact on T cell activation and myeloid cell polarization conducted in collaboration with the National Cancer Institute at ... |
NXTC Price Returns
| 1-mo | 16.54% |
| 3-mo | -7.19% |
| 6-mo | -21.98% |
| 1-year | -45.17% |
| 3-year | -67.16% |
| 5-year | N/A |
| YTD | -22.50% |
| 2021 | -44.95% |
| 2020 | -80.65% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...